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http://dx.doiabstractBACKGROUND: Alternating hemiplegia of childhood (AHC) is a rare condition characterized by an early onset of
hemiplegic episodes and other paroxysmal or permanent neurological dysfunctions. Recently, mutations in the
ATP1A3 gene have been identiﬁed as the causal mechanism of AHC. Regarding the differential diagnosis of AHC,
glucose transporter 1 deﬁciency syndrome may be considered because these two disorders share some paroxystic
and nonparoxystic features. PATIENT AND RESULTS:We report a typical case of AHC harboring a de novo mutation in
the ATP1A3 gene, together with a duplication and insertion in the SLC2A1 gene who exhibited marked clinical
improvement following ketogenic diet. CONCLUSION: Because the contribution of the SLC2A1 mutation to the clinical
phenotype cannot be deﬁnitely demonstrated, the remarkable clinical response after ketogenic diet led us to the
hypothesis that ketogenic diet might be effective in AHC as it provides an alternative energy source for the brain.
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Alternating hemiplegia of childhood (AHC) is a rare
disease characterized by repeated episodes of hemiplegia
with onset before 18months of age, tonic ordystonic attacks,
paroxysmal features, such as abnormal eye movements,
dyspnea, and other autonomic phenomena with disappear-
ance of all symptoms in sleep, in association with develop-
mental delay, mental retardation and other neurological
abnormalities.1-3 Recently, mutations in the ATP1A3 gene
have been identiﬁed as one important cause of AHC.4-6ory:
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.org/10.1016/j.pediatrneurol.2013.11.017As part of the differential diagnosis of AHC, glucose
transporter 1 (GLUT1) deﬁciency syndrome (GLUT1 DS)
may be considered since these two disorders share several
peculiar paroxystic and nonparoxystic features. GLUT1 DS is
a neurological disease caused by reduced transport of
glucose across the blood-brain barrier due to hap-
loinsufﬁciency of the SLC2A1 gene.7 The most common
manifestations of GLUT1 DS include epilepsy, develop-
mental delay, acquired microcephaly, spasticity, ataxia,
dystonia and, additionally or alternatively, paroxysmal
dyskinesia.8-10 Other phenotypes also have been reported,
including the nonclassical phenotype of mental retardation
and movement disorders without epilepsy; the spectrum of
severity in this disease is really broad.9,10
We report a girl with AHC and a mutation in the ATP1A3
gene that also harbors an intronic duplication and insertion
in the SLC2A1 gene. The patient exhibited a favorable,
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marked improvement with adjunctive treatment with a
ketogenic diet. There is a lack of previous conﬁrmed asso-
ciation between AHC and GLUT1 DS so this the ﬁrst case
reported.
Case report
We present a 10-year-old girl with an unremarkable family history.
She was the third child of healthy, unrelated parents. Pregnancy and
neonatal period were normal (gestational age: 40 weeks, weight: 3230 g,
height: 49 cm, head circumference: 34 cm). At 5 months of age, she ﬁrst
manifested mild episodes of global hypotonia associated with clonic
movements of both hands without impairment of consciousness. At
10 months of age, she developed episodes of ﬁne tremor followed by
cephalic ﬂexion and convergent strabismus lasting up to 24 hours, all of
which ceased with sleep. Microcephaly (head circumference <5th
percentile) and global developmental delay became noticeable. At
12months of age, she developed alternating hemiplegia, with a right-side
predilection, lasting fromminutes to hours, provoked by physical exercise
and fasting and which improved with sleep. In light of the dystonic
episodes, abnormal eye movements, developmental delay and alter-
nating hemiplegia, she was diagnosed with AHC. Ancillary examinations
(electroencephalogram, cerebral ultrasound, brain magnetic resonance
imaging, and auditory-evoked potentials) were normal. Laboratory
investigations to rule out inborn errors of metabolism (blood count,
electrolytes, renal function, ammonium, lactate, creatine kinase, plasma
amino acids, urinary organic acids) and karyotype also were normal.
The combination of developmental delay, microcephaly, and dystonic
movements provoked by fasting suggested a neurometabolic disorder, so
a lumbar puncture was performed when she was 3 years old. Cerebro-
spinal ﬂuid (CSF) analysis showed a glucose concentration at the lower
limit of normal range (2.6 mmol/L; reference value for age:
2.4-3.8 mmol/L) with a CSF/blood glucose ratio of 0.54 (reference value
for age: 0.43-0.86) and lactate of 1.4 mmol/L (reference value
1.0-2.0 mmol/L).11 To complement this observation, 18F-deoxyglucose
proton emission tomography (18FDG-PET) was performed while the
patient was asymptomatic, but 2 weeks after an hemiplejic attack,
revealing high 18F-FDG accumulation in the basal ganglia, particularly in
the putamen and caudate nuclei, in contrast with the cerebral cortex (Fig
A). Because this pattern resembles that identiﬁed in GLUT1 DS, SLC2A1FIGURE.
(A) PET images show high 18F-FDG uptake in the basal ganglia, particularly in pu
after starting ketogenic diet show normal and symmetrical 18F-FDG uptake in
emission tomography; PET, positron emission tomography.mutational analysis was performed via DNA sequencing. A noncoding
duplication (tactcacc) and an insertion (atat) of unknown signiﬁcance in
intron 9-10were identiﬁed. The contribution of this variant (if any) to the
imaging phenotype is unknown at this time. However, the ATP1A3 gene
was sequenced and a de novo mutation at position c.C2411 T was found,
resulting in the predicted amino acid substitution T804I.
Given the AHC phenotype, at 4 years of age, treatment with ﬂunar-
izine was started, leading to shortening (but not the disappearance) of
the events. In light of this relative treatment failure, CSF studies, 18FDG-
PET results and the identiﬁcation of molecular changes of unknown
relevance in SLC2A1, adjunctive treatment with a ketogenic diet (ratio
4:1) was initiated. The paroxysmal events almost completely dis-
appeared, becoming milder, shorter, and less frequent. Before starting
the diet, the patient had one hemiplegic attack weekly, and after starting
the diet she presented hemiplegic attacks every 6 months. She also
experienced improvement in motor function also was noticed: before
the ketogenic diet, the patient required awheelchair for outdoor use, but
afterwards she was able to walk independently. Follow-up 18FDG-PET
(under ketogenic diet, while the patient was asymptomatic and 1 month
after the last hemiplegic attack) exhibited normal and symmetrical
18F-FDG uptake in the basal ganglia, as well as in the cortex (Fig B). The
mechanism underlying these changes remains unknown and it probably
differs from that responsible for GLUT1 DS, in which PET ﬁndings have
never proven amenable to evolution (JM Pascual, unpublished observa-
tions, n ¼ 67 and an additional n ¼ 14).12 The patient has been on
ketogenic diet for 4 years, and she is still receiving ﬂunarizine.
Discussion
AHC is a rare disorder (with an estimated prevalence of 1
in 1 million children) ﬁrst described by Verret and Steele in
1971. Krakelog and Aicardi established the clinical
diagnostic criteria currently in use in 1980.2,3 AHC is char-
acterized by hemiplegic, tonic, or dystonic episodes and
abnormalities of ocular movements with onset before
18 months of age, as well as global neurological dysfunc-
tion.1,8 Hemiplegic events often can be related to environ-
mental triggers such as physical activity, insufﬁcient food
intake or certain foods, whereas symptoms are usually
relieved by sleep.3 The diagnosis of AHC relied on clinicaltamen and caudate, clearly greater than the normal cortex. (B) PET images
basal ganglia as well as in the cortex. 18F-FDG, 18F-deoxyglucose proton
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as a primary cause of AHC.4-6 This gene encodes the a-3
subunit of the sodium-potassium ATPase, which is prefer-
entially expressed in the basal ganglia, hippocampus and
cerebellum.5 Flunarizine, a calcium channel blocker,
decreases frequency, severity and duration of attacks,
demonstrating partial efﬁcacy in at least 70% of patients,2 as
was observed in our patient.
First described in 1991, GLUT1 DS is a disorder of brain
energy metabolism caused by diminished brain glucose
entry.13,14 Severe epilepsy, developmental delay, acquired
microcephaly, spasticity, and dystonia are common mani-
festations.8,9 Among the epileptic and early events, apnea
and episodic eye movements are common in GLUT1 DS and
in AHC.13 The spectrum of GLUT1 DS is very broad, and the
neurological symptoms that it causes have been divided
three domains: epilepsy, movement disorders, and cogni-
tive/behavioral disturbances.9 Paroxysmal events are also
characteristic of GLUT1 DS and include intermittent ataxia,
lethargy, somnolence, alternating hemiparesis, total body
paralysis, and headaches, which are also features shared by
AHC.13 An aid for the diagnosis of patients with paroxysmal
events is the fact that they are triggered by fasting and
exercise.9 GLUT1 DS can be diagnosed by demonstrating
hypoglycorrhachia in CSF in the context of a normal serum
glucose and a low CSF lactate.8,9 18FDG-PET generally
shows hypometabolism in the mesial temporal regions and
thalami, with relative signal increase in the basal ganglia15
as revealed in our patient. The ketogenic diet is the most
widely used treatment in GLUT1 DS, affording seizure
mitigation and improvement in other neurological symp-
toms in some patients.7,9
Our patient harbored a duplication and insertion in an
intron of the SLC2A1 gene, which is not expected to alter
GLUT1 transporter structure, although effects on mRNA
expression or stability have not been investigated. This
mutation is overrepresented in GLUT1 DS, but it can occur
in nonaffected relatives, making the potential contribution
of this additional mutation to the pathogenesis of AHC
undetermined (5 of 55 GLUT1 DS cases, only the proband
described in this report exhibited an AHC phenotype, and 2
of 104 related asymptomatic controls; JM Pascual, unpub-
lished observation). In support of a co-causal role of this
variant, 18FDG-PET studies, biochemical analysis of CSF, and
the response to a ketogenic diet support the involvement of
impaired glucose transport as a phenotypic modiﬁer in our
patient. In this regard, our patient suggests novel hypothe-
ses. In the presence of potentially impaired sodium homeo-
stasis in the basal ganglia caused byamutation at theATP1A3
gene, subtle changes in brain glucose transport might cause
additional deleterious effects. However, studies in Spanish
and French cohorts have failed to detectmutations in SLC2A1
in a total of 53 AHC patients,8 such that this matter will
deserve further investigation since it is evident that these
two diseases share symptoms, including movement disor-
ders. In the French cohort (23 patients), 14 exhibited normal
glucose CSF levels, whereas 9 remained undetermined.8
Our patient fulﬁlled all criteria for AHC and improved
with ﬂunarizine treatment. She also displayed clinical and
analytical features overlapping with those of GLUT1 DS and,
although the contribution of SLC2A1mutation to the clinical
phenotype cannot be deﬁnitely demonstrated, 18FDG-PETdata and a favorable clinical outcome after a ketogenic diet
could support the potential implication of GLUT1 DS in the
phenotype of our AHC patient. But because the implication
of the SLC2A1mutation is not clear, there is also a possibility
that AHC itself might beneﬁt from a ketogenic diet. The
ketogenic diet might work as ketones provide an alternative
energy source for the brain. Also ketogenic diet might
reduce neuronal excitability, present in AHC because of the
increased intracellular sodium concentration, and in this
way reduce the paroxysmal symptoms. Therefore, investi-
gation of the interrelation between sodium, ATP and
glucose homeostasis in the brain is expected to shed light
on potentially synergistic disease mechanisms.
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